Nurix Therapeutics’ (NRIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock. A number of other equities research analysts also recently commented on NRIX. BTIG Research initiated coverage on Nurix Therapeutics in […]